# A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple- Dose BIVV009 in Participants With Chronic Immune Thrombocytopenia (ITP)

> **NCT03275454** · PHASE1 · COMPLETED · sponsor: **Bioverativ, a Sanofi company** · enrollment: 12 (actual)

## Conditions studied

- Purpura, Thrombocytopenic, Idiopathic

## Interventions

- **DRUG:** BIVV009 6.5 grams
- **DRUG:** BIVV009 7.5 grams

## Key facts

- **NCT ID:** NCT03275454
- **Lead sponsor:** Bioverativ, a Sanofi company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-14
- **Primary completion:** 2021-02-16
- **Final completion:** 2021-02-16
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2023-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03275454

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03275454, "A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple- Dose BIVV009 in Participants With Chronic Immune Thrombocytopenia (ITP)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03275454. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*